5-(5-fluoro-3-methyl-1-naphthalen-2-ylmethyl-1H-indol-7-yl)-isoxazol-3-ylamine | 885225-99-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-(5-fluoro-3-methyl-1-naphthalen-2-ylmethyl-1H-indol-7-yl)-isoxazol-3-ylamine
• 英文别名: 5-[5-Fluoro-3-methyl-1-(naphthalen-2-ylmethyl)indol-7-yl]-1,2-oxazol-3-amine
• CAS: 885225-99-0
• 化学式: C₂₃H₁₈FN₃O
• 分子量: 371.414
• InChiKey: YAPWLVFQGWVELA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  57
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4,5-三氟苯磺酰氯 、 5-(5-fluoro-3-methyl-1-naphthalen-2-ylmethyl-1H-indol-7-yl)-isoxazol-3-ylamine 在 吡啶 、 4-二甲氨基吡啶 作用下， 以19%的产率得到2,4,5-trifluoro-N-[5-(5-fluoro-3-methyl-1-naphthalen-2-ylmethyl-1H-indol-7-yl)-isoxazol-3-yl]-benzenesulfonamide
  参考文献：
  名称：

  A general approach to indole-7-yl derivatives of isoxazole, oxadiazole, thiadiazole and pyrazole

  摘要：

  Isosteric replacement of the alpha,beta-unsaturated amide at the C-7 position of indoles with a diverse set of five-membered amino-heterocycles including isoxazole, oxadiazole, thiadiazole and pyrazole followed by subsequent derivatization of the heterocyclic amino group to yield amides, sulfonamides and phosphoramides is described. Distinctive features of these procedures include the versatility and robust nature of the synthetic steps along with the high yields of the targeted molecules. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.11.073
• 作为产物：
  描述：

  3-(5-fluoro-3-methyl-1-naphthalen-2-ylmethyl-1H-indol-7-yl)-3-oxo-propionitrile 在 硫酸羟胺 、 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 19.0h， 生成 5-(5-fluoro-3-methyl-1-naphthalen-2-ylmethyl-1H-indol-7-yl)-isoxazol-3-ylamine
  参考文献：
  名称：

  A general approach to indole-7-yl derivatives of isoxazole, oxadiazole, thiadiazole and pyrazole

  摘要：

  Isosteric replacement of the alpha,beta-unsaturated amide at the C-7 position of indoles with a diverse set of five-membered amino-heterocycles including isoxazole, oxadiazole, thiadiazole and pyrazole followed by subsequent derivatization of the heterocyclic amino group to yield amides, sulfonamides and phosphoramides is described. Distinctive features of these procedures include the versatility and robust nature of the synthetic steps along with the high yields of the targeted molecules. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.11.073

文献信息

• Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
  申请人：Singh Jasbir

  公开号：US20060142348A1

  公开（公告）日：2006-06-29

  Aryl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

  本发明揭示了用于治疗或预防前列腺素介导的疾病或病状的芳基磺酰胺，周围取代，融合双环环化合物。该化合物的一般式如下：其中，代表性的例子为：
• ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE
  申请人：Singh Jasbir

  公开号：US20090075985A1

  公开（公告）日：2009-03-19

  Aryl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

  本发明公开了一种对假性脂质体介导的疾病或病症有治疗或预防作用的芳基磺酰胺、邻位取代、融合双环环化合物。该化合物的一般式如下：其中，代表性例子为：
• A general approach to indole-7-yl derivatives of isoxazole, oxadiazole, thiadiazole and pyrazole
  作者：Alexandre M. Polozov、Georgeta Hategan、Hua Cao、Alex S. Kiselyov、Wayne Zeller、Jasbir Singh

  DOI：10.1016/j.tetlet.2009.11.073

  日期：2010.1

  Isosteric replacement of the alpha,beta-unsaturated amide at the C-7 position of indoles with a diverse set of five-membered amino-heterocycles including isoxazole, oxadiazole, thiadiazole and pyrazole followed by subsequent derivatization of the heterocyclic amino group to yield amides, sulfonamides and phosphoramides is described. Distinctive features of these procedures include the versatility and robust nature of the synthetic steps along with the high yields of the targeted molecules. (C) 2009 Elsevier Ltd. All rights reserved.